The prevalence of CYP2C19 mutations in Turkish patients with dyspepsia

Senturk, Omer; ÇELEBİ, Altay; KOCAMAN, Orhan; HÜLAGÜ, Sadettin; KONDUK, BUĞRA TOLGA; Savli, Hakan; AYGÜN, Cem

The prevalence of CYP2C19 mutations in Turkish patients with dyspepsia

Altay ÇELEBİ, (Kocaeli Üniversitesi, Tıp Fakültesi, Gastroenteroloji Anabilim Dalı, Kocaeli, Türkiye)

Orhan KOCAMAN, (Kocaeli Üniversitesi, Tıp Fakültesi, Gastroenteroloji Anabilim Dalı, Kocaeli, Türkiye)

Hakan SAVLI, (Kocaeli Üniversitesi, Tıp Fakültesi, Tıbbi Genetik Anabilim Dalı, Kocaeli, Türkiye)

Cem AYGÜN, (Kocaeli Üniversitesi, Tıp Fakültesi, Gastroenteroloji Anabilim Dalı, Kocaeli, Türkiye)

Buğra Tolga KONDUK, (Kocaeli Üniversitesi, Tıp Fakültesi, Gastroenteroloji Anabilim Dalı, Kocaeli, Türkiye)

Ömer ŞENTÜRK, (Kocaeli Üniversitesi, Tıp Fakültesi, Gastroenteroloji Anabilim Dalı, Kocaeli, Türkiye)

Sadettin HÜLAGÜ (Kocaeli Üniversitesi, Tıp Fakültesi, Gastroenteroloji Anabilim Dalı, Kocaeli, Türkiye)

Turkish Journal of Gastroenterology

0 0

Yıl: 2009 Cilt: 20 Sayı: 3 Sayfa Aralığı: 161 - 164 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

The prevalence of CYP2C19 mutations in Turkish patients with dyspepsia

Öz:

Amaç: Dispeptik yakınmaları olan Türk hastalarda cytocrom P450 2C19 enziminin genotipik dağılımını belirlemek. Yöntem: Dispeptik yakınmaları olan 100 Türk hastada CYP2C19 genotipi belirlendi. Hastaların DNA'lı kandan ayrıldı ve genotipler real-time PCR ile spesifik problarla saptandı. Bulgular: Dispeptik hastalarda heterozigot CYP2C19*2 ve CYP2C19*3 genotipi sırasıyla %13 ve %1 saptandı. Çalışma hastalarının sadece birinde (%1) homozigot mutant CYP2C19*2 saptandı. Dispeptik hastalarda homozigot mutant CYP2C19*3 bulunmadı. Dispeptik Türk hastalarda homozigot CYP2C19*2 ve CYP2C19*3 genotipleri sırasıyla %86 ve %99 olarak bulundu. Sonuç: Bu araştırma dispeptik Türk hastalarda CYP2C19 polimorfizminin araştırıldığı ilk çalışmadır. Çalışmamız dispeptik Türk hastalarda en sık görülen CYP2C19 genotiplerinin homozigot CYP2C19*2 ve CYP2C19*3 olduğunu göstermektedir. Dispeptik Türk hastalar Proton Pompa İnhibitörleri için hızlı metabolize edicidirler. Bu bulgular dispepsi tedavisinin klinik sonuçlarında etkili olabilir.

Anahtar Kelime: Erişkin Genotip Hastalığa genetik yatkınlık Homozigot Dispepsi Türkiye Yaygınlık Orta yaşlı

Konular: Cerrahi

Dispeptik yakınmaları olan Türk hastalarda CYP2C19 mutasyonlarının prevelansı

Öz:

Background/aims: We aimed to determine the distribution of cytochrome P450 2C19 (CYP2C19) genotype frequencies in Turkish patients with dyspepsia. Methods: CYP2C19 genotype was determined in 100 Turkish patients with dyspepsia. DNA of the patients was isolated from whole blood and genotypes were detected by specific probes in real-time polymerase chain reaction (PCR). Results: The frequencies of heterozygous CYP2C19*2 and CYP2C19*3 genotypes were 13% and 1% in dyspeptic patients, respectively. Homozygous mutant CYP2C19*2 was detected at a rate of only 1% in the study population, and homozygous mutant genotype of CYP2C19*3 was not found. The frequencies of homozygous CYP2C19*2 and CYP2C19*3 genotypes were 86% and 99% in dyspeptic Turkish patients, respectively. Conclusions: This is the first study investigating CYP2C19 polymorphism in dyspeptic Turkish patients. Our investigation revealed that the most common CYP2C19 genotype was wild type CYP2C19 in dyspeptic Turkish patients. Dyspeptic Turkish patients are extensive metabolizers for proton pump inhibitors. This finding might have impact on the clinical consequences for the treatment strategies in dyspepsia.

Anahtar Kelime: Dyspepsia Turkey Prevalence Middle Aged Adult Genotype Genetic Predisposition to Disease Homozygote

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Goldstein JA. Clinical relevance of genetic polymorphism in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349-55.
2. Dickson EJ, Stuart RC. Genetics of response to proton pump inhibitor therapy. Am J Pharmacogenomics 2003; 3: 303-5.
3. Rosemary J, Adithan C, Padmaja N, et al. The effect of the CYP2C19 genotype on the hydroxylation index of omeprazole in South Indians. Eur J Clin Pharmacol 2005; 61: 19- 23.
4. Van Zanten SV, Thompson K. Should the presence of polymorphisms of CYP2C19 enzymes influence the choice of the proton pump inhibitor for treatment of Helicobacter pylori infection? Am J Gastroenterol 2006; 101: 1476-8.
5. Drossman DA. Rome III: the new criteria. Chin J Dig Dis 2006; 7: 181-5.
6. Chong E, Ensom M. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003; 23: 460-71.
7. Talley NJ, Vakil N. Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005; 100: 2324-37.
8. Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1- week triple therapies. Gastroenterology 1999; 116: 248-53.
9. Talley NJ. Therapeutic options in nonulcer dyspepsia. J Clin Gastroenterol 2001; 32: 286-93.
10. Tanum L, Malt UF. A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo- controlled study with Mianserin. Scand J Gastroenterol 1996; 31: 318-25.
11. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9: 442-73.

APA	ÇELEBİ A, KOCAMAN O, Savli H, AYGÜN C, KONDUK B, Senturk O, HÜLAGÜ S (2009). The prevalence of CYP2C19 mutations in Turkish patients with dyspepsia. , 161 - 164.
Chicago	ÇELEBİ Altay,KOCAMAN Orhan,Savli Hakan,AYGÜN Cem,KONDUK BUĞRA TOLGA,Senturk Omer,HÜLAGÜ Sadettin The prevalence of CYP2C19 mutations in Turkish patients with dyspepsia. (2009): 161 - 164.
MLA	ÇELEBİ Altay,KOCAMAN Orhan,Savli Hakan,AYGÜN Cem,KONDUK BUĞRA TOLGA,Senturk Omer,HÜLAGÜ Sadettin The prevalence of CYP2C19 mutations in Turkish patients with dyspepsia. , 2009, ss.161 - 164.
AMA	ÇELEBİ A,KOCAMAN O,Savli H,AYGÜN C,KONDUK B,Senturk O,HÜLAGÜ S The prevalence of CYP2C19 mutations in Turkish patients with dyspepsia. . 2009; 161 - 164.
Vancouver	ÇELEBİ A,KOCAMAN O,Savli H,AYGÜN C,KONDUK B,Senturk O,HÜLAGÜ S The prevalence of CYP2C19 mutations in Turkish patients with dyspepsia. . 2009; 161 - 164.
IEEE	ÇELEBİ A,KOCAMAN O,Savli H,AYGÜN C,KONDUK B,Senturk O,HÜLAGÜ S "The prevalence of CYP2C19 mutations in Turkish patients with dyspepsia." , ss.161 - 164, 2009.
ISNAD	ÇELEBİ, Altay vd. "The prevalence of CYP2C19 mutations in Turkish patients with dyspepsia". (2009), 161-164.

APA	ÇELEBİ A, KOCAMAN O, Savli H, AYGÜN C, KONDUK B, Senturk O, HÜLAGÜ S (2009). The prevalence of CYP2C19 mutations in Turkish patients with dyspepsia. Turkish Journal of Gastroenterology, 20(3), 161 - 164.
Chicago	ÇELEBİ Altay,KOCAMAN Orhan,Savli Hakan,AYGÜN Cem,KONDUK BUĞRA TOLGA,Senturk Omer,HÜLAGÜ Sadettin The prevalence of CYP2C19 mutations in Turkish patients with dyspepsia. Turkish Journal of Gastroenterology 20, no.3 (2009): 161 - 164.
MLA	ÇELEBİ Altay,KOCAMAN Orhan,Savli Hakan,AYGÜN Cem,KONDUK BUĞRA TOLGA,Senturk Omer,HÜLAGÜ Sadettin The prevalence of CYP2C19 mutations in Turkish patients with dyspepsia. Turkish Journal of Gastroenterology, vol.20, no.3, 2009, ss.161 - 164.
AMA	ÇELEBİ A,KOCAMAN O,Savli H,AYGÜN C,KONDUK B,Senturk O,HÜLAGÜ S The prevalence of CYP2C19 mutations in Turkish patients with dyspepsia. Turkish Journal of Gastroenterology. 2009; 20(3): 161 - 164.
Vancouver	ÇELEBİ A,KOCAMAN O,Savli H,AYGÜN C,KONDUK B,Senturk O,HÜLAGÜ S The prevalence of CYP2C19 mutations in Turkish patients with dyspepsia. Turkish Journal of Gastroenterology. 2009; 20(3): 161 - 164.
IEEE	ÇELEBİ A,KOCAMAN O,Savli H,AYGÜN C,KONDUK B,Senturk O,HÜLAGÜ S "The prevalence of CYP2C19 mutations in Turkish patients with dyspepsia." Turkish Journal of Gastroenterology, 20, ss.161 - 164, 2009.
ISNAD	ÇELEBİ, Altay vd. "The prevalence of CYP2C19 mutations in Turkish patients with dyspepsia". Turkish Journal of Gastroenterology 20/3 (2009), 161-164.